After Monday's roller coaster on the markets, Tuesday brought another cooling of the temperature on the stock exchange floors. WIG20, which started the session with slight increases, ended the day in decline, dragged down by bank shares. The shares of medium-sized companies also performed poorly. Single stocks, such as Trans Polonia and Pure Biologics, shined on the broad market.
While Monday began with panic in the markets, and later in the day it turned into a state of euphoria after the US President's entry about steps towards ending the war with Iran, Tuesday revised investors' expectations. While Donald Trump talked about negotiations with the Islamic Republic going in the right direction, no talks have yet taken place.
Highly placed Reuters sources in Tehran revealed to journalists that their country intends to set tough negotiating conditions and wants to demand “significant concessions” from the United States. Iran's course was supposed to stiffen by strengthening the power of the Islamic Revolutionary Guard Corps in the country.
Advertisement
Global indices presented a mixed picture on Tuesday. In most cases, we observed a recovery on Asian stock exchanges after Monday's declines. The Nikkei strengthened by 1.43%. and Hang Seng and KOSPI increased by 2.74 and 2.79 percent, respectively.
The day started with declines on the American stock markets. When trading ended on the WSE, the S&P500 and Nasdaq lost 0.16%, respectively. and 0.62 percent At that time, the German DAX was close to the reference point, and the CAC40 was strengthening by 0.43%.
WIG20 lost 0.82%, falling to 3,241.42 points, which was the lowest closing session this year. WIG decreased by 0.88%. The MWIG40 mid-cap index saw an even greater decline, losing 1.24%. By 0.37 percent SWIG80 fell on Tuesday.
The turnover on the broad market amounted to nearly PLN 2.2 billion, of which PLN 1.84 billion was accounted for by trading in shares of companies from the WIG20 index.
Orlen and Żabka are up, CD Projekt and Allegro are down
In the WSE blue chip index, only three companies ended the session in positive territory: Żabka (+2.28%), Orlen (+1.87%) and Pepco (+0.79%).
The shares of CD Projekt (-3.57%) and Allegro (-2.56%) were the most depreciated in the WIG20 index.
The securities of the largest Polish banks were a heavy burden for WIG20. PKO BP fell by 2.04%, and Alior Bank withdrew by 2.06%. 1.64 percent Pekao shares went down.
Reaction to the results of the WSE and Ten Square Games
By 4.4 percent The shares of the Warsaw Stock Exchange dropped on Tuesday when it announced its results for the fourth quarter. The stock exchange emphasized that last year was a record year for it in terms of revenues and profits. The latter increased by over 30% in the fourth quarter. year to year, reaching PLN 204.7 million. The value of session turnover on the WSE main market amounted to PLN 470.3 billion, which means a year-on-year increase of 41.9%. Despite this, the company was one of the weakest links in the MWIG40 index that day.
The results of Ten Square Games (-6.55%) were also met with a negative market reaction. Adjusted EBITDA turned out to be 11 percent. lower than the consensus of analyst forecasts and by 35 percent. lower than a year ago. Investors were not placated by the announcement of a PLN 10 dividend per share (over PLN 5 less than last year).
Pure and Trans Polonia's ratings skyrocket
25.88 percent On Tuesday, the prices of Trans Polonia – a transport company that announced that it had submitted an offer to take over an unnamed much larger player in the industry – went up. The company plans to obtain financing, among others: through banks, PFR and private debt funds, avoiding issuance. The subject of the takeover is to be an entity worth PLN 2 billion, while Trans Polonia was valued at PLN 320 million after Tuesday's session.
Pure Biologics shares achieved an even greater percentage increase, gaining as much as 38.78%. On March 24, the company published an ESPI announcement in which it stated that the results of the study of the drug candidate helpful in the fight against cancer confirm its intended mechanism of action in humans and support the validity of further clinical development of the project.
MM
The publication contains affiliate links.
